Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144805 | 0.99 | BDKRB1 (0.50) | BDKRB1KCNH2L3MBTL1RXFP1GPR27 | |
| SCHEMBL15104002 | 0.89 | BDKRB1 (0.49) | BDKRB1KCNH2GPR27CCR2 | |
| SCHEMBL15103949 | 0.88 | BDKRB1 (0.48) | BDKRB1KCNH2GPR27CCR2 | |
| SCHEMBL3145186 | 0.86 | BDKRB1 (0.67) | BDKRB1KCNH2L3MBTL1RXFP1LMNA | |
| SCHEMBL3153277 | 0.85 | BDKRB1 (0.66) | BDKRB1KCNH2L3MBTL1RXFP1 | |
| SCHEMBL3274494 | 0.85 | CCR2 (0.46) | BDKRB1KCNH2GPR27CCR2 | |
| SCHEMBL3157696 | 0.84 | CCR2 (0.51) | KCNH2L3MBTL1RXFP1HRH3CCR2 | |
| SCHEMBL3153878 | 0.83 | CCR2 (0.50) | KCNH2L3MBTL1RXFP1CCR2 | |
| SCHEMBL3148147 | 0.82 | CCR2 (0.49) | KCNH2L3MBTL1RXFP1CCR2 | |
| SCHEMBL3148887 | 0.81 | CCR2 (0.53) | KCNH2L3MBTL1RXFP1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | BDKRB1 1/4885KCNH2 80/4885L3MBTL1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.